JPWO2021010712A5

JPWO2021010712A5 -

Info

Publication number: JPWO2021010712A5
Application number: JP2022503414A
Authority: JP
Publication date: 2023-07-24

Claims

the following:
a heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1;
heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO:2; and heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO:3
A heavy chain variable region (VH), comprising:
a light chain CDR1 having the amino acid sequence represented by SEQ ID NO:4;
light chain CDR2 having the amino acid sequence represented by SEQ ID NO:5; and light chain CDR3 having the amino acid sequence represented by SEQ ID NO:6
light chain variable region (VL)
An anti-tau antibody or antigen-binding fragment thereof, comprising:

The anti-tau antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises any one amino acid sequence selected from the group consisting of SEQ ID NOS: 7-11, and the light chain variable region comprises any one amino acid sequence selected from the group consisting of SEQ ID NOS: 12-15.

An antibody or antigen-binding fragment thereof that:
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:7 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:12;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:8 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:14;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:9 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:15;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 13;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 14;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region having the amino acid sequence represented by SEQ ID NO: 15;
an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having the amino acid sequence represented by SEQ ID NO:11 and a light chain variable region having the amino acid sequence represented by SEQ ID NO:13;
2. The anti-tau antibody or antigen-binding fragment thereof according to claim 1, which is any one selected from the group consisting of: an anti-tau antibody or antigen-binding fragment thereof comprising a heavy chain variable region having an amino acid sequence represented by SEQ ID NO: 11 and a light chain variable region having an amino acid sequence represented by SEQ ID NO: 14;

2. The anti-tau antibody or antigen-binding fragment thereof of claim 1, wherein the fragment is any one selected from the group consisting of Fab, scFv, F(ab')2 and Fv.

A polynucleotide encoding the anti-tau antibody or antigen-binding fragment thereof of claim 1 .

An expression vector comprising the polynucleotide of claim 5 .

A host cell comprising the expression vector of claim 6 .

9. A method for producing the anti-tau antibody or antigen-binding fragment thereof of claim 1, said method comprising culturing the host cell of claim 7.

A polynucleotide encoding an antibody heavy or light chain comprising a heavy chain variable region and a light chain variable region as described in claim 2.

Hybridoma with accession number KCTC 14155BP.

A pharmaceutical composition for preventing or treating degenerative neurological diseases, said pharmaceutical composition comprising the anti-tau antibody or antigen-binding fragment thereof of claim 1 as an active ingredient.

Degenerative neurological disease is a tau protein-mediated neurological diseasethe law of nature,Here, tau protein-mediated neurological disorders include tauopathy, primary age-related tauopathy, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Ritcho-Bodyg disease, parkinsonism, subacute sclerosing meningitis, leadenencephalosis, tuberous sclerosis, ganglioglioma, gangliocytoma, meningohemangiomatosis, subacute sclerosing panencephalitis, Hallerholden- spp. Spatz's disease, or lipofuscinosis, where tauopathies are collectively referred to as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal dementia (CBD), Pick's disease (PiD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). a group-related disorder, amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), boxing dementia (DP), Gerstmann-Straussler-Scheinker disease (GSSD), Lewy body disease, chronic traumatic encephalopathy (CTE), or Huntington's disease.A pharmaceutical composition according to claim 11 .

12. The pharmaceutical composition of claim 11, which is administered via any one route of administration selected from the group consisting of intracerebral, intracerebroventricular, intraperitoneal, transdermal, intramuscular, intradural, intravenous, subcutaneous, and nasal routes of administration.

12. The pharmaceutical composition of claim 11, wherein prophylaxis or treatment comprises administering an anti-tau antibody or antigen-binding fragment thereof of claim 1 to a subject predicted to develop or currently having a degenerative neurological disease.

A composition for diagnosing neurodegenerative disease, said composition comprising the anti-tau antibody or antigen-binding fragment thereof of claim 1 .

A kit for preventing, treating or diagnosing a degenerative neurological disease, said kit comprising the antibody or antigen-binding fragment thereof of claim 1, the polynucleotide of claim 5, the expression vector of claim 6, or the host cell of claim 7.

Use of the antibody or antigen-binding fragment thereof of claim 1 for preparing a medicament used to prevent or treat degenerative neurological diseases.